financetom
Business
financetom
/
Business
/
GAIL expects LNG prices to settle down as new projects start commissioning
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GAIL expects LNG prices to settle down as new projects start commissioning
Jun 25, 2018 3:54 AM

As new liquefied natural gas (LNG) projects start commissioning, prices will settle down to normal level as supply increases, said BC Tripathi, Chief Managing Director, GAIL.

India's state-owned natural gas utility, GAIL, has recently switched its focus to short-term and spot deals for the purchase of LNG to meet rising demand and hedge against price volatility.

Speaking to CNBC-TV18, Tripathi said the company is not a beneficiary, when the prices are high for consumers as the increase is because of market moments based on supply-demand situations.

However, the company is focusing on how to optimise the supply, and cut down the cost of procurement, shipping with various optimisation tools, so that prices are affordable to the consumers, Tripathi added.

According to him, prices will remain at the current levels and expect to come down because of some global changes and increase in China’s LNG demand.

Tripathi said the proposed hike in transmission tariffs is due to to low capacity utilisation of the pipeline and any infrastructure projects cannot sustain longer if it's not given assured or reasonable rate of return.

Discussions with government and Petroleum and Natural Gas Regulatory Board (PNGRB) is on and aim is to create a situation, where it's balance for all the consumers and for the companies investing in the infrastructure, he said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Elicio Therapeutics' ELI-002 7P Candidate Shows Positive T cell Responses in Ongoing Phase 2 Trial
Elicio Therapeutics' ELI-002 7P Candidate Shows Positive T cell Responses in Ongoing Phase 2 Trial
Oct 27, 2025
08:37 AM EDT, 10/27/2025 (MT Newswires) -- Elicio Therapeutics ( ELTX ) said Monday that preliminary analysis from its phase 2 trial indicated that 99% of patients assessed for Human Leukocyte Antigen background induced mKRAS-specific T cell responses after treatment with ELI-002 7P. The induction of mKRAS-specific T cell responses suggest that ELI-002 7P may address a broad patient population...
Parkland Q3 Adjusted Earnings Rise 70% Ahead of its US$9.1-Billion Sale to Sunoco
Parkland Q3 Adjusted Earnings Rise 70% Ahead of its US$9.1-Billion Sale to Sunoco
Oct 27, 2025
08:33 AM EDT, 10/27/2025 (MT Newswires) -- Parkland (PKI.TO) Monday said its third-quarter adjusted profit rose 70% in its final report ahead of the company's sale to Sunoco ( SUN ) . The refiner and gas-stop operator's adjusted profit, excluding most one-time items, rose to $180 million, or $1.03 per share, from $106 million, or $0.61, in the year-prior quarter....
Organon Appoints Joseph Morrissey as Interim CEO After Investigation Finds Possible Sales Practice Irregularities
Organon Appoints Joseph Morrissey as Interim CEO After Investigation Finds Possible Sales Practice Irregularities
Oct 27, 2025
08:33 AM EDT, 10/27/2025 (MT Newswires) -- Organon (OGN) said Monday its board has appointed the company's head of manufacturing and supply Joseph Morrissey as interim CEO. Morrissey was most recently the head of Merck's ( MRK ) animal health global manufacturing and supply division, Organon said. Kevin Ali, previously CEO, resigned after an audit discovered possible sales practice irregularities...
BCB Bancorp Q3 net income falls 36%, but interest margins rise
BCB Bancorp Q3 net income falls 36%, but interest margins rise
Oct 27, 2025
Overview * BCB Bancorp ( BCBP ) Q3 net income falls to $4.3 mln from $6.7 mln a year ago * EPS for Q3 2025 was $0.22, down from $0.36 in Q3 2024 * Net interest margin increased to 2.88% in Q3 2025 from 2.58% a year earlier Outlook * Company did not provide specific guidance for future quarters or...
Copyright 2023-2026 - www.financetom.com All Rights Reserved